Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.

You may also be interested in...



Safety Problems Help AstraZeneca Win Suit Brought By Former Partner Verus

AstraZeneca is in a strange position for a pharmaceutical company: It has benefited in court because of safety problems observed in one of its products

Safety Problems Help AstraZeneca Win Suit Brought By Former Partner Verus

AstraZeneca is in a strange position for a pharmaceutical company: It has benefited in court because of safety problems observed in one of its products

Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market

Which kinds of innovations make for incremental enhancements in the hands of large companies and which are meaningful enough to sustain a venture-backed start-up company? In a mature market for coronary stents dominated by large companies, start-ups developing new stents need to find the answers. Areas of innovation fall into four basic categories: improving stent safety and biocompatibility, avoiding the need for dual antiplatelet therapy, enhancing deliverability, and introducing specialty stents for complex vessels. Three companies profiled here have a plan for taking sufficient market share, reducing risk, and rewarding investors.

Related Content

Topics

UsernamePublicRestriction

Register

PS069483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel